维多珠单抗治疗炎症性肠病的机制与临床应用研究进展

Vedolizumab for treatment of inflammatory bowel disease: research progress of clinical applications and mechanisms

炎症性肠病(IBD)是一类病因未明的肠道慢性复发性炎症性疾病,其治疗仍以传统药物为主。由于传统药物不良反应较明显,近年来衍生出多种生物制剂,如抗肿瘤坏死因子(TNF)制剂、整合素拮抗剂等。作为一种人源化的抗α4β7整合素单克隆抗体,维多珠单抗(Vedolizumab)通过抑制α4β7整合素与黏膜地址素细胞黏附分子-1(MAdCAM-1)相互作用,选择性阻断记忆T细胞向炎症肠道组织转运,减轻肠道炎症反应,因而主要用于对抗TNF生物制剂失效的IBD患者。本文对维多珠单抗治疗IBD的机制、临床疗效及安全性进行综述。

Inflammatory bowel disease (IBD) is a kind of chronic, relapsing inflammatory disease of the gastrointestinal tract with unknown etiology. Its treatment is still dominated by traditional medicine. Due to the obvious adverse reactions of these traditional drugs, a variety of biological agents have been derived in recent years, such as anti-tumor necrosis factor (TNF) biological agents, integrin antagonists. As a humanized anti-α4β7 integrin monoclonal antibody, vedolizumab can selectively block trafficking of memory T cells to inflamed intestinal tissues by inhibiting the interaction of α4β7 integrin with mucosal address cell adhesion molecule-1, reducing intestinal inflammation. Therefore, it is mainly used in IBD patients who are failed to respond to the anti-TNF biological agents. This review will discuss the mechanism, clinical efficacy and safety of vedolizumab in the treatment of IBD.